AUTH/2298/2/10: GSK Consumer Healthcare NiQuitin mailing—PK data presentation implied quit-rate superiority and breached prior undertakings

📊

Key facts

⌄

Case number	AUTH/2298/2/10
Parties	Johnson & Johnson/Director v GlaxoSmithKline Consumer Healthcare
Product	NiQuitin 21mg Clear Patch (nicotine replacement therapy)
Material type	Mailing (leaflet + covering letter)
Material reference	NCQ/SYN/KG/1109/01
Date of preparation	December 2009
Complaint received	23 February 2010
Case completed	14 June 2010
Applicable Code year	2008
Appeal	No appeal
Breach Clause(s)	2 (x2), 7.2 (x7), 7.3 (x3), 9.1 (x2) and 25 (x2)
Sanctions applied	Undertaking received

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

What happened

⌄

Johnson & Johnson complained about a December 2009 mailing (leaflet + covering letter; ref NCQ/SYN/KG/1109/01) promoting NiQuitin 21mg Clear Patch (NRT).
The leaflet headline asked: “Which therapeutic nicotine patch delivers more nicotine faster than any other patch?” and presented pharmacokinetic (PK) graphs and comparative messaging versus other patches (including Nicorette and Nicotinell).
One key claim (“From day one NiQuitin 21mg Clear Patch delivers more nicotine faster than any other therapeutic nicotine patch”) was challenged as ambiguous/misleading; the Panel found no breach for that specific claim when read with the graph.
However, the overall leaflet layout (three consecutive pages moving from PK graphs to “Proven short- and long-term quit rates”) was found to imply that favourable PK profiles caused superior quit outcomes, without proof.
“Top parity” style claims (eg “No other patch has been shown to be more effective…”) were found misleading in context and not capable of substantiation across all relevant comparators (eg lack of 4-week data for Nicotinell 21mg was noted).
The covering letter repeated PK and effectiveness messaging and included statements about nocturnal dosing and cravings; the Panel found the letter also implied unproven causal links and superiority in cessation.
Because possible breaches of prior undertakings (from AUTH/1253/11/01 and AUTH/1401/12/02) were alleged, the Director took up that part of the case to ensure compliance with undertakings.

⚖️

Outcome

⌄

Breach findings (overall case): Clause(s) 2 (x2), 7.2 (x7), 7.3 (x3), 9.1 (x2) and 25 (x2).
No breach for the specific claim: “From day one NiQuitin 21mg Clear Patch delivers more nicotine faster than any other therapeutic nicotine patch” (no breach of Clause 7.2 for that point).
No breach for: “~60% of abrupt quitters remain quit at 4 weeks with NiQuitin 21mg Clear Patch” (no breach of Clause 7.2).
No breach for: “~20% of quitters remain quit at 52 weeks with NiQuitin 21mg Clear Patch” (no breach of Clause 7.2).
Breach where PK/craving content and the way it was presented implied improved quit rates (causal link not established), and where “no other patch…” claims were likely to be read as superiority claims in a comparative leaflet.
Breach of undertakings found (Clause 25), including where the Panel considered the material contrary to undertakings given in earlier cases.

🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

Key facts

What happened

Outcome

Clauses

Unlock the full case analysis

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown